It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cancer-associated fibroblasts (CAFs), as a central component of the tumor microenvironment in primary and metastatic tumors, profoundly influence the behavior of cancer cells and are involved in cancer progression through extensive interactions with cancer cells and other stromal cells. Furthermore, the innate versatility and plasticity of CAFs allow their education by cancer cells, resulting in dynamic alterations in stromal fibroblast populations in a context-dependent manner, which highlights the importance of precise assessment of CAF phenotypical and functional heterogeneity. In this review, we summarize the proposed origins and heterogeneity of CAFs as well as the molecular mechanisms regulating the diversity of CAF subpopulations. We also discuss current strategies to selectively target tumor-promoting CAFs, providing insights and perspectives for future research and clinical studies involving stromal targeting.
Cancer: Reprogramming cells that support tumors
Tumors reprogram nearby wound-healing cells into cancer-associated fibroblasts (CAFs) to support their metabolism, escape the immune response and develop resistance to chemotherapy; targeting CAFs may provide therapeutic opportunities. CAFs are very diverse, and their origins and specific roles are not well understood. New genetic tools allow precise profiling of CAFs and their functions, and Dakai Yang at Jiangsu University in Zhenjiang, China, and co-workers have reviewed CAF diversity and the mechanisms by which they are generated. Although most CAFs support tumors, some CAFs fight tumors, and they can potentially be converted from one form to another. Improving our understanding of the variety of CAFs, their functions, and how they interact with tumor cells may help in identifying tumor-suppressing CAFs and in developing precision medicine treatments for various types of cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Affiliated Hospital of Jiangsu University, Department of General Practice, Zhenjiang, People’s Republic of China (GRID:grid.452247.2); Jiangsu University, Department of Laboratory Medicine, School of Medicine, Zhenjiang, People’s Republic of China (GRID:grid.440785.a) (ISNI:0000 0001 0743 511X)
2 Microbiology and Immunity Department, Shanghai, People’s Republic of China (GRID:grid.440785.a); Shanghai University of Medicine & Health Sciences, Collaborative Innovation Center for Biomedicines, Shanghai, People’s Republic of China (GRID:grid.507037.6) (ISNI:0000 0004 1764 1277)
3 Jiangsu University, Department of Laboratory Medicine, School of Medicine, Zhenjiang, People’s Republic of China (GRID:grid.440785.a) (ISNI:0000 0001 0743 511X)
4 Affiliated Hospital of Jiangsu University, Department of General Practice, Zhenjiang, People’s Republic of China (GRID:grid.452247.2)